Should You Chase The Breakout In Eli Lilly Stock?

This pharma giant’s recent run is grabbing headlines, but its long-term behavior tells a more interesting story about portfolio risk.

Eli Lilly (LLY) just capped a strong week, climbing 10.0% even as the broader S&P 500 slid 2.0%. The move came on the heels of a positive recommendation from a European regulatory committee for its cancer drug, Jaypirca, potentially expanding its use for treating chronic lymphocytic leukemia.

In a falling market, that kind of standout performance creates a powerful instinct. It’s the urge to chase the winner, to find the one stock that seems to be defying gravity.

But the question that actually builds your wealth isn’t where a stock will go next week. It’s about what owning it does to the risk of your entire portfolio. How much of its performance is its own, unique story, and how much is just the same market you already own through an index fund?

A Different Engine For Your Portfolio

Over the last five years, Eli Lilly’s stock has shown a low correlation to the S&P 500, at just 0.31. That number tells you that most of its returns have been driven by its own business, largely independent of the market’s day-to-day swings. For an investor looking to add a single stock to an indexed portfolio, that’s an attractive profile; it adds a return stream you aren’t already getting.

This low correlation translates into a tangible advantage. Over the past year, the stock has demonstrated a genuinely favorable asymmetry. On days the S&P 500 rose, LLY captured about 81% of the market’s gain. But on days the market fell, it absorbed only about 34% of the market’s loss. It has offered participation in the upside while providing a meaningful cushion on the downside.

Paired with its strong performance, this has led to a risk-adjusted return of 1.13 over five years, well ahead of the S&P 500’s 0.61.

The Business Behind The Breakout

This distinct behavior is rooted in a business running at full tilt. On its latest earnings call, management reported that revenue grew 56% compared to the same quarter last year, driven by its blockbuster cardiometabolic drugs Mounjaro and Zepbound, which together brought in $12.8 billion in the first quarter. The company is so confident that it raised its full-year revenue guidance by $2 billion.

The challenge is that this growth comes at a premium. The stock trades at a price-to-earnings ratio of 42.8, far above the S&P 500 median of 24.4. The biggest question hanging over the company is whether it can secure broad, long-term insurance coverage for its high-demand obesity treatments. Management has been clear that gaining this access “won’t be a straight line” and expects pricing to be a “headwind in the low to mid-teens for the full year.”

So what does owning Eli Lilly stock do for you? The numbers suggest it acts as a differentiated return engine. Its low correlation means it provides a distinct return stream, one driven by its own pipeline and commercial success instead of broad market trends.

Concretely, owning it has meant catching most of the market’s good days while being insulated from two-thirds of the bad ones.

The one business signal to watch is the progress on insurance coverage. The long-term sustainability of its volume growth depends heavily on converting more employers and health plans to cover its obesity drugs, turning a self-pay phenomenon into a staple of chronic care.

Zoom out from Eli Lilly for a second, because the deeper question is not this one stock but your whole portfolio. Real steadiness comes from owning names that do not all sink at once when the market turns, and the prize is the ones that manage it while still earning their keep. Our correlation rankings are built for exactly that search: they rank S&P 500 stocks by how loosely each tracks the market alongside its one-year return, so you can spot the names that cushion you against market swings without costing you performance.

Where Does Eli Lilly Fit In Your Portfolio?

Knowing how one stock behaves is the easy part. The hard part is the decision it leads to: how much of it to hold, and what to pair it with, so a single name’s swings never come to dominate your results. That answer depends on everything else you own, which is the calculation most investors never actually run.

The Trefis High Quality (HQ) Portfolio runs it for you, weighing how each holding behaves alongside the others rather than on its own, inside a disciplined 30-stock core that is re-balanced as the picture changes and judged on far more than any single signal. It has outpaced a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000.